Clinical Trial Update: Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of ibrutinib and rituximab in relapsed or refractory mantle cell lymphoma and in older patients with newly dia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: CCND1 Positive, CCND2 Positive | Phase 2 | Status: ACTIVE_NOT_RECRUITING